Tyra Biosciences (TYRA) Projected to Post Earnings on Thursday

by · The Cerbat Gem

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) is projected to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Tyra Biosciences to post earnings of ($0.50) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.06. On average, analysts expect Tyra Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tyra Biosciences Price Performance

TYRA opened at $15.24 on Thursday. Tyra Biosciences has a fifty-two week low of $6.42 and a fifty-two week high of $17.78. The firm has a market capitalization of $812.25 million, a PE ratio of -8.56 and a beta of 1.11. The company’s 50-day moving average is $13.21 and its 200 day moving average is $11.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of TYRA. Millennium Management LLC grew its position in shares of Tyra Biosciences by 28.2% during the 1st quarter. Millennium Management LLC now owns 404,165 shares of the company’s stock valued at $3,759,000 after acquiring an additional 89,024 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Tyra Biosciences by 21.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company’s stock valued at $725,000 after acquiring an additional 13,896 shares during the period. Woodline Partners LP bought a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $931,000. Jane Street Group LLC bought a new position in shares of Tyra Biosciences during the 1st quarter valued at approximately $324,000. Finally, Geode Capital Management LLC grew its position in shares of Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company’s stock valued at $5,428,000 after acquiring an additional 50,836 shares during the period. 84.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Raymond James Financial assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating and a $35.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Tyra Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research report on Friday, August 22nd. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Get Our Latest Report on TYRA

About Tyra Biosciences

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Read More